Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression profile of HLA-B*38:55Q allele.
Fusco C, Cervelli C, Dal Mas A, Canossi A, Azzarone R, Valdez O, Auriemma L, Madalese D, Maisto G, Toriello M, Penta de Vera d'Aragona R, Scimitarra M, Scarnecchia MA, Battistoni C, Fracassi D, Papola F. Fusco C, et al. Among authors: dal mas a. HLA. 2020 May;95(5):449-456. doi: 10.1111/tan.13790. Epub 2020 Jan 6. HLA. 2020. PMID: 31891446
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: dal mas a. BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135. BMC Med. 2012. PMID: 23136868 Free PMC article.
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C. Cocciolone V, et al. Among authors: dal mas a. Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270. eCollection 2018 Jun 8. Oncotarget. 2018. PMID: 29937992 Free PMC article.
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.
Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C. Cortellini A, et al. Among authors: dal mas a. Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019. Onco Targets Ther. 2019. PMID: 30988620 Free PMC article.
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, Calvisi G, Troncone G, Simmaco M, Ricevuto E. Bruera G, et al. Among authors: dal mas a. Ther Adv Med Oncol. 2019 May 10;11:1758835919846421. doi: 10.1177/1758835919846421. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31205502 Free PMC article.
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice.
Bruera G, Pepe F, Malapelle U, Di Staso M, Dal Mas A, Di Giacomo D, Scerbo G, Santilli M, Ciacco E, Simmaco M, Troncone G, Coco C, Giuliante F, Ricevuto E. Bruera G, et al. Among authors: dal mas a. Ann Transl Med. 2021 Jun;9(12):1027. doi: 10.21037/atm-20-6636. Ann Transl Med. 2021. PMID: 34277827 Free PMC article.
27 results